G01N 2333/71
For growth factors
Official title: for growth factors; for growth regulators
G01N2333/71 (For growth factors) appears on 587 US grants and 1,023 published applications in this corpus.
Search patents in G01N- Granted patents
- 587
- Published applications
- 1,023
- Assignees
- 553
- Inventors
- 1,958
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1988 | 1 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 2 | 0 |
| 1995 | 2 | 0 |
| 1996 | 3 | 0 |
| 1997 | 4 | 0 |
| 1998 | 17 | 0 |
| 1999 | 15 | 0 |
| 2000 | 7 | 0 |
| 2001 | 6 | 3 |
| 2002 | 6 | 14 |
| 2003 | 8 | 23 |
| 2004 | 2 | 18 |
| 2005 | 11 | 29 |
| 2006 | 10 | 26 |
| 2007 | 6 | 21 |
| 2008 | 16 | 32 |
| 2009 | 16 | 48 |
| 2010 | 23 | 55 |
| 2011 | 27 | 51 |
| 2012 | 20 | 46 |
| 2013 | 24 | 42 |
| 2014 | 26 | 46 |
| 2015 | 29 | 88 |
| 2016 | 33 | 65 |
| 2017 | 47 | 84 |
| 2018 | 35 | 62 |
| 2019 | 31 | 39 |
| 2020 | 45 | 35 |
| 2021 | 31 | 43 |
| 2022 | 17 | 25 |
| 2023 | 15 | 31 |
| 2024 | 24 | 27 |
| 2025 | 15 | 33 |
| 2026 | 11 | 37 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods for selecting and treating cancer with FGFR3 inhibitors29 Sep 2026US 12,748,103 B2GeneCentric Therapeutics, Inc.
- Anti-FGFR2B antibodies1 Sep 2026US 12,723,091 B2Dizal (Jiangsu) Pharmaceutical Co., Ltd.
- Monoclonal antibodies to fibroblast growth factor receptor 214 Jul 2026US 12,679,897 B2Galaxy Biotech, LLC
- Systems, methods and compositions for analysis of proteoforms7 Jul 2026US 12,674,807 B2Nautilus Subsidiary, Inc.
- Methods for making radiolabeled anti-MET binding proteins21 Apr 2026US 12,605,473 B2Regeneron Pharmaceuticals, Inc.
- Anti-cmet antibody, antibody-drug conjugate, and preparation method therefor and use thereof8 Oct 2026US 2026/0306651 A1MediLink Therapeutics (Suzhou) Co., Ltd.
- Systems for identifying proteoforms of tau protein24 Sep 2026US 2026/0287600 A1Nautilus Subsidiary, Inc.
- Method and kit for the diagnosis of oral carcinoma17 Sep 2026US 2026/0276642 A1
- Antibody against c-met and use thereof20 Aug 2026US 2026/0242488 A1
- Method for evaluating receptor-type tyrosine kinase activity20 Aug 2026US 2026/0243779 A1Riken
Most cited
By later US patents
- Tissue analysis and kits therefor193US 6,573,043 B1Genentech, Inc. · 2003
- ErbB3 antibodies156US 5,968,511 AGenentech, Inc. · 1999
- Compounds and therapies for the prevention of vascular and non-vascular pathologies146US 6,117,911 ANeoRx Corporation · 2000
- High affinity human antibodies to tumor antigens134US 5,977,322 AThe Regents of the University of California · 1999
- Methods for eliciting or enhancing reactivity to HER-2/neu protein131US 5,869,445 AUniversity of Washington · 1999